Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Breast CareDNA replication and recombination inhibited by anthracyclines.In a recent analysis of the Canadian trial NCIC CTG MA5, which compared 6 cycles CMF (cyclophosphamide/ methotrexate/5-fluorouracil) versus CE120F (cyclophosphamide/epirubicin/5-fluorouracil) in 710 premenopausal women, TOP 2A status, however, did not reach significance as a prognostic factor for disease-free or overall survival [5].The TOP 2A status can, therefore, be characterized as an interesting area of research, but should not be assessed routinely in clinical practice.The predictive value of ErbB2 overexpression for a high responsiveness to taxanes is still a matter of debate.The improved clinical efficacy seen with combinations of trastuzumab plus chemotherapy in the metastatic setting led to the initiation of 4 large adjuvant trials with this monoclonal antibody with a combined recruitment of more than 13,000 women with ErbB2-overxpressing early breast cancer.With the exception of trial BCIRG 006, these trials did not combine different cytotoxic schedules with trastuzumab.At present, it is therefore not possible to discriminate chemotherapeutic regimens optimally suited for the incorporation of trastuzumab.On the basis of the BCIRG 006 data, however, it can be concluded that trastuzumab can be effectively combined with a schedule of doxorubicine/cyclophosphamide (AC), followed by docetaxel and with carboplatin/docetaxel, with the latter having the advantage of less cardiotoxicity [6]. Unanswered Questions in Adjuvant Trastuzumab TherapyFour adjuvant trials have demonstrated the benefit of adding trastuzumab to conventional chemotherapy in terms of improving recurrence-free and overall survival [6][7][8].The positive results of the first interim analyses were confirmed by updates of NCCTG N9831 and NSABP B-31 as well as
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it